Skip to main content

Press releases 2015

2015-12-30
STOCKHOLM, December 30, 2015. The number of shares and votes in Moberg Pharma AB (publ) has increased by 215,985 to 14,217,522 during December 2015. Therefore, there are in total 14,217,522 shares and votes in the company as of July 31, 2015.
2015-12-22
STOCKHOLM, December 22, 2015. Moberg Pharma AB (OMX: MOB) today announced that topline data from the clinical phase II-study for BUPI is expected to be announced in January
2015-11-17
In accordance with the resolution of the Annual General Meeting on May 11, 2015, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 11.
2015-11-10
CONTINUED GROWTH AND DOUBLING OF PROFIT
2015-11-10
STOCKHOLM, November 10, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that it has reached an agreement with its partner Meda to regain rights to Emtrix® in certain EU markets where the nail product has not yet been launched, including UK and Poland.
2015-11-03
STOCKHOLM, November 3, 2015. Moberg Pharma AB (OMX: MOB) today announced that Moberg Pharma and Colep – a leading global player in the consumer goods packaging and contract manufacturing industries – entered a Development Agreement for MOB-015 – a novel topical formulation of terbinafine for onychomycosis (nail fungus).
2015-08-11
CONTINUED SEQUENTIAL GROWTH
2015-07-31
STOCKHOLM, July 31, 2015. The number of shares and votes in Moberg Pharma AB (publ) has increased by 39,000 to 14,001,537 during July 2015. Therefore, there are in total 14,001,537 shares and votes in the company as of July 31, 2015.
2015-06-24
STOCKHOLM, June 24, 2015. Moberg Pharma AB (OMX: MOB) today announced that a grant of EUR 0.9 million in public funding has been approved by Eurostars for a project proposal related to late-stage development of Moberg Pharma’s BUPI project.
2015-05-28
STOCKHOLM, May 28, 2015. Moberg Pharma AB (OMX: MOB) today announced that the European Patent Office  has issued patent no. 2,777,689 for an improved formulation of Moberg Pharma’s market-leading OTC product for the treatment of fungal nails, sold in the U.S. under the Kerasal Nail® brand. The patent expires in 2034.
2015-05-19
STOCKHOLM, May 19th, 2015. Moberg Pharma AB (OMX: MOB) today announced that its partner, Menarini Asia-Pacific, has initiated the launch of Kerasal Nail® in China. TV commercials and other advertising started this week in certain parts of southern China.
2015-05-11
STOCKHOLM, May 11, 2015. Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Monday, May 11, 2015 in the Company´s premises in Bromma.
2015-05-11
RAPID GROWTH IN SALES AND PROFITABILITY
2015-04-27
STOCKHOLM, April 27, 2015. Moberg Pharma AB (OMX: MOB) has acquired Balmex®, a well-established Over-The-Counter brand in the U.S. from Chattem, Inc, the U.S. Consumer Healthcare Division of Sanofi. Net sales of the brand is trending on an annual rate exceeding $4 million. The purchase price is $3.9 million and financed by available cash resources.
2015-04-09

Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Monday, May 11, 2015 at 5:00 p.m. in the Company´s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.

2015-04-09
Moberg Pharma's Annual Report for 2014 has been published and is available on www.mobergpharma.com
2015-03-26
STOCKHOLM, March 26, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that the European Patent Office has issued Patent no. 2 672 962, relating to its topical treatment MOB-015 for onychomycosis (nail fungus). The patent is expected to be in effect until 2032.  In September 2014, Moberg Pharma reported positive results from a Phase II study of MOB-015 and in January 2015, received similar patent approval in the U.S.
2015-03-25
STOCKHOLM, March 25, 2015. Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,987,330 for Moberg Pharma’s market-leading product Kerasal Nail®, an over-the-counter (OTC) product for fungal nails. The patent expires in 2034.
2015-03-13
STOCKHOLM, March 13, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that Professor Jan Faergemann, Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden and Principal Investigator of the phase-II clinical trial on the Company’s product candidate for onychomycosis MOB-015, will present at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) on March 22, 2015 in San Francisco, CA.
2015-03-12
STOCKHOLM, March 12, 2015 - Moberg Pharma AB (STO: MOB) today announced that Emtrix® Fungal Nail Treatment has reached a market leading position  in Malaysia with 45% market share* for the full year of 2014. In the fourth quarter of 2014, Emtrix was launched in Malaysia by Moberg Pharma's partner Menarini APAC. Advertising and TV commercials began in November / December and has continued in the new year with continued strong sales.
2015-03-04
STOCKHOLM, March 4, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that it will ship opening orders of its first aid product Domeboro® in over 3,500 Walmart stores within the next week. 
2015-02-27
SUCCESSFUL FOURTH QUARTER AND THE FIRST PROFITABLE FULL YEAR
2015-02-18
STOCKHOLM, February 18, 2015 -- On February 27, at 08:00 CET, Moberg Pharma AB (OMX: MOB) will publish its report for the fourth quarter and full year 2014 (note: changed date).
2015-02-13
STOCKHOLM, February 13, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that it shipped opening orders of its new line extension, Kerasal® Complete Care in Walgreens, the #1 drug chain in the U.S., with additional retailers expected to follow.
2015-02-11
STOCKHOLM, January 11, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,952,070, relating to its topical treatment MOB-015 for onychomycosis. The patent is expected to be in effect until 2032. In September 2014, Moberg Pharma reported positive results from a Phase II study of MOB-015.
2015-02-09
STOCKHOLM, February 9, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine.
2015-01-27
Moberg Pharma AB (OMX: MOB) today announced that its partner, Menarini Asia-Pacific, has received approval for Moberg’s fungal nail product in China. Launch preparations in several markets are progressing ahead of plan.